Myriad Genetics Strengthens MRD Technology with New Patent
Myriad Genetics, Inc. (NASDAQ: MYGN) is making significant strides in the field of genetic testing and precision medicine. Recently, they announced that the United States Patent and Trademark Office has granted them a third patent that enhances their capacity to provide an advanced, high-definition molecular residual disease (MRD) assay. This notable development reflects the company's commitment to improving oncology care through innovative solutions.
Understanding the Importance of the New Patent
The newly issued U.S. patent number 12,104,212 is titled "Personalized Methods for Detecting Circulating Tumor DNA." This patent is crucial as it reinforces Myriad's ongoing initiatives to augment their MRD strategy. The patent protects proprietary methods that allow for the ultra-sensitive detection of tumor-specific mutations in circulating tumor DNA (ctDNA), which is pivotal for effective cancer management.
Complementary Patents and Progress
Earlier in the year, Myriad Genetics announced the issuance of two complimentary patents focused on foundational MRD technology. These patents cover cell-free DNA preparation methods that enhance the sensitivity and specificity of tumor-informed, sequencing-based MRD assays, including their innovative Precise MRD test.
CEO's Vision for the Future
Paul J. Diaz, the President and CEO of Myriad Genetics, emphasized the significance of this third MRD patent. He stated, "The issuance of this third MRD patent supports Myriad's efforts to establish a proprietary and differentiated MRD assay that tracks up to thousands of tumor-specific variants." This capability enables detection of ctDNA at significantly lower levels compared to existing options in the market. The development of the Precise MRD assay builds on Myriad's existing technology, notably the FDA-approved MyChoice CDx companion diagnostic and FirstGene platforms.
Collaborative Efforts and Research
Myriad Genetics is dedicated to advancing its Precise MRD assay to not only meet the demands of cancer patients but also support academic partners and biopharmaceutical companies. Currently, the test is involved in several high-impact studies while transitioning to an advanced laboratory facility. They have announced various collaborations, including studies focusing on metastatic breast cancer with Memorial Sloan Kettering and metastatic renal cell carcinoma with The University of Texas MD Anderson Cancer Center.
About Myriad Genetics
Myriad Genetics stands as a leader in the domains of genetic testing and precision medicine, aiming to enhance health and well-being globally. The company offers a variety of genetic tests designed to evaluate disease risk and guide treatment decisions, significantly improving patient care and reducing healthcare costs.
Frequently Asked Questions
What is the significance of the new patent granted to Myriad Genetics?
The new patent strengthens Myriad Genetics' ability to deliver highly sensitive MRD assays, which are crucial for cancer management.
How does the MRD assay work?
The MRD assay detects tumor-specific mutations in circulating tumor DNA (ctDNA), allowing for early monitoring of cancer recurrence.
Who are Myriad Genetics' collaborators in cancer research?
Myriad partners with various institutions, including Memorial Sloan Kettering and The University of Texas MD Anderson Cancer Center, for high-impact studies.
What are the main applications of the Precise MRD assay?
The Precise MRD assay is used for tracking tumor variants and monitoring patients in clinical studies related to cancer.
Where can I find more information about Myriad Genetics?
More details about Myriad Genetics and their offerings can be found on their website, www.myriad.com.
